Akebia Therapeutics Inc  

(Public, NASDAQ:AKBA)   Watch this stock  
Find more results for Teresa Rice´┐Ż
-0.27 (-3.50%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.38 - 7.87
52 week 5.91 - 14.20
Open 7.64
Vol / Avg. 312,016.00/819,148.00
Mkt cap 292.20M
P/E     -
Div/yield     -
EPS -2.13
Shares 37.90M
Beta     -
Inst. own 48%
Feb 8, 2016
Akebia Therapeutics Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference - 11:30AM EST - Add to calendar
Dec 14, 2015
Akebia Therapeutics Inc And Mitsubishi Tanabe Pharma Corp Collaboration Announcement -Conference Call
Nov 10, 2015
Akebia Therapeutics Inc at Credit Suisse Healthcare Conference
Nov 9, 2015
Q3 2015 Akebia Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -49.56% -50.85%
Return on average equity -52.93% -
Employees 41 -
CDP Score - -


245 1st St Ste 1100
CAMBRIDGE, MA 02142-1292
United States - Map
+1-617-8712098 (Phone)
+1-617-8712099 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. The Company's lead product candidate, AKB-6548, is being developed as a once-daily, oral therapy. It has completed a Phase IIb study demonstrating that AKB-6548 can raise hemoglobin levels in non-dialysis patients with anemia related to chronic kidney disease (CKD). The Company is also conducting a Phase II study for the treatment of anemia in patients undergoing dialysis. The Company's preclinical candidate, AKB-6899, is a small molecule with minor structural differences from its lead compound AKB-6548. AKB-6899 is being developed for the treatment of certain cancers.

Officers and directors

John M. Rice Ph.D. Chairman of the Board
Bio & Compensation  - Reuters
John P Butler President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Jason A Amello Chief Financial Officer, Senior Vice President, Treasurer
Bio & Compensation  - Reuters
Teresa Compton Senior Vice President, Chief Scientific Officer
Bio & Compensation  - Reuters
Brad Maroni M.D. Senior Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Nicole R. Hadas Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Tamara Dillon Vice President - Human Resources
Bio & Compensation  - Reuters
Ed Joyce Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Mark De Rosch Ph.D. Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Ramin Farzaneh-Far MD Vice President - Medical Research
Bio & Compensation  - Reuters